Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00300456 · ClinicalTrials.gov registry record · Phase 3
Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 657
- Enrollment target
NCT00300456 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 657 participants.
The verdict
NCT00300456, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 657 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
Interventions
- DRUG Placebo
- DRUG Simvastatin
- DRUG ABT-335
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 657 participants |
| Start Date | 2006-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00300456
The ClinicalTrials.gov registry entry for NCT00300456 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 657 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00300456 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00300456 about?
NCT00300456 is a clinical study titled "Evaluate Safety and Efficacy of ABT-335 in Combination With Simvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood". The purpose of this study is to compare the safety and efficacy of fenofibric acid (ABT-335) + simvastatin combination therapy with ABT-335 and simvastatin monotherapy in subjects with multiple abnormal lipid levels in the blood.
What is the current status of trial NCT00300456?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 657 participants. The study started on 2006-03.
What interventions are being tested in trial NCT00300456?
The interventions under investigation include: Placebo (DRUG), Simvastatin (DRUG), ABT-335 (DRUG).
Who is sponsoring clinical trial NCT00300456?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.